ATE441420T1 - Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen - Google Patents

Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen

Info

Publication number
ATE441420T1
ATE441420T1 AT02292963T AT02292963T ATE441420T1 AT E441420 T1 ATE441420 T1 AT E441420T1 AT 02292963 T AT02292963 T AT 02292963T AT 02292963 T AT02292963 T AT 02292963T AT E441420 T1 ATE441420 T1 AT E441420T1
Authority
AT
Austria
Prior art keywords
subject
gamma delta
regulating
immune response
compositions containing
Prior art date
Application number
AT02292963T
Other languages
English (en)
Inventor
Francois Romagne
Helene Sicard
Jerome Tiollier
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of ATE441420T1 publication Critical patent/ATE441420T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT02292963T 2002-12-02 2002-12-02 Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen ATE441420T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02292963A EP1426052B1 (de) 2002-12-02 2002-12-02 Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen

Publications (1)

Publication Number Publication Date
ATE441420T1 true ATE441420T1 (de) 2009-09-15

Family

ID=32309486

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02292963T ATE441420T1 (de) 2002-12-02 2002-12-02 Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
AT03768074T ATE459360T1 (de) 2002-12-02 2003-12-02 Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03768074T ATE459360T1 (de) 2002-12-02 2003-12-02 Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen

Country Status (8)

Country Link
US (2) US20060194755A1 (de)
EP (2) EP1426052B1 (de)
JP (1) JP2006510629A (de)
AT (2) ATE441420T1 (de)
AU (1) AU2003292492B2 (de)
CA (1) CA2507011A1 (de)
DE (2) DE60233576D1 (de)
WO (1) WO2004050096A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
US7767842B2 (en) * 2002-12-02 2010-08-03 Innate Pharma Sa Class of γδ T cells activators and use thereof
US20100291118A1 (en) * 2003-12-02 2010-11-18 Innate Pharma Class of Gamma Delta T Cells Activators and Use Thereof
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen
WO2005102385A1 (en) 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
US8153426B2 (en) * 2004-08-19 2012-04-10 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy
EP1802641B8 (de) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonatverbindungen und -verfahren für knochenschwundkrankheiten, krebs, knochenschmerzen, immunstörungen und infektionskrankheiten
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
EP1863572A2 (de) * 2005-03-22 2007-12-12 Innate Pharma Neue t-zellaktivatorklasse und verwendung
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
JP2009530414A (ja) 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
US20100144678A1 (en) * 2007-04-09 2010-06-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating bone cancer
EP2150258A2 (de) * 2007-06-01 2010-02-10 Innate Pharma S.A. Verbessertes verfahren zur verwendung von phosphoantigenen in verbindung mit interleukin-2 zur krebsbehandlung
WO2009131730A2 (en) 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
EP2123285A1 (de) 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosid-Phosphorantigene zur Verwendung in der VGAMMA9VDELTA2-T-Zellen-vermittelten Therapie
EP2324040B1 (de) 2008-09-10 2014-01-01 Innate Pharma Neue polymorphe form von chdmapp, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
ES2811624T3 (es) * 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
DK2683395T3 (en) * 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
WO2014072446A1 (en) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for inducing il-2-free proliferation of gamma delta t cells
JP2016530298A (ja) 2013-09-05 2016-09-29 サンフォード−バーンハム メディカル リサーチ インスティテュート γδＴ細胞の調節
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
WO2021073290A1 (en) * 2019-10-17 2021-04-22 The University Of Hong Kong Methods to prepare v-t cells derived exosomes for treatment of epstein-barr virus-associated cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896871B2 (en) * 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
WO2000000158A2 (en) * 1998-06-30 2000-01-06 The Brigham And Women's Hospital, Inc. Alkylamines and their precursors as specific modulators of human gamma-delta t cell function
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
ATE313547T1 (de) * 1999-01-21 2006-01-15 Chugai Pharmaceutical Co Ltd 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
PT1178810E (pt) * 1999-05-21 2005-08-31 Novartis Ag Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
DE50212935D1 (de) * 2001-07-20 2008-12-04 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen

Also Published As

Publication number Publication date
AU2003292492B2 (en) 2008-10-23
WO2004050096A2 (en) 2004-06-17
US20060194755A1 (en) 2006-08-31
EP1426052A1 (de) 2004-06-09
JP2006510629A (ja) 2006-03-30
ATE459360T1 (de) 2010-03-15
US20100254940A1 (en) 2010-10-07
DE60331583D1 (de) 2010-04-15
EP1569656A2 (de) 2005-09-07
EP1569656B1 (de) 2010-03-03
EP1426052B1 (de) 2009-09-02
AU2003292492A1 (en) 2004-06-23
DE60233576D1 (de) 2009-10-15
CA2507011A1 (en) 2004-06-17
WO2004050096A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE441420T1 (de) Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
SG151278A1 (en) Oral and personal care compositions and methods
MY206158A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
ATE365534T1 (de) Kosmetische hautpflegezusammensetzungen
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
GB0209891D0 (en) Novel compounds
FI935585A0 (fi) Pyrrolopyrimidiner
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
WO2003088931A3 (en) Polymeric odor absorption ingredients for personal care products
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
ATE405261T1 (de) Verwendung von castanospermine derivaten in der behandlung von hepatitis c
MXPA03001673A (es) Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas.
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
WO2003057856A3 (en) Dominant negative proteins and methods thereof
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
TW200501993A (en) Oral care compositions and methods
ATE457992T1 (de) Platinkomplexe und deren verwendung in der therapie
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
YU38103A (sh) Nova jedinjenja askorbinske kiseline, postupci sinteze i način njihove primene
DE50310932D1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
DK1513551T3 (da) Vaccination med immun-isolerede celler, der producerer en immunomodulator

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties